Resumen de Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain
Cristina Grávalos Castro, Pilar García Alfonso, Ruth Afonso, Virginia Arrazubi Arrula, Antoni Arrivi, Juan Carlos Cámara Vicario, Jaume Capdevila Castillon, M. A. Gómez España, Adelaida Lacasta, José Luis Manzano Mozo, Mercedes Salgado Fernández, Javier Sastre Valera, Eduardo Díaz-Rubio García
In Spain 22,000 new cases of colorectal cancer are diagnosed each year, with 13,075 deaths resulting from this disease. Around 70% of colorectal cancers are localised in the colon and 30% in the rectum. A group of Spanish experts established recommendations on what would be the best strategy in the treatment of locally advanced rectal cancer (LARC). Adequate assessment of local tumour extension, including high-resolution magnetic resonance imaging and endorectal ultrasound, is essential for successful treatment. The three cornerstones in the treatment of LARC are surgery, radiotherapy and chemotherapy. Most patients will need a total mesorectal excision (TME). Preoperative chemo-radiotherapy (CRT) is preferred for the majority of patients with T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended after a patient-sharing decision. Capecitabine, after showing a trend in improved downstaging in neoadjuvant stratum and the convenience of its oral administration, represents an alternative to 5-FU as perioperative treatment of LARC.
